Similar articles

• Fixed-dose combination therapy (polypill) for the prevention of cardiovascular disease.

  Huffman MD, de Cates AN, Ebrahim S. Huffman MD, et al. JAMA. 2014 Nov 19;312(19):2030-1. doi: 10.1001/jama.2014.13616. JAMA. 2014. PMID: 25399279
• One pill, four questions: what we still need to know about reducing cardiovascular risk with combination therapy.

  Hughes AD. Hughes AD. Cochrane Database Syst Rev. 2014 Apr 16;2014(4):ED000079. doi: 10.1002/14651858.ED000079. Cochrane Database Syst Rev. 2014. PMID: 24818243 Free PMC article. No abstract available.
• A polypill is the solution to the pharmacological management of cardiovascular risk: no.

  Toop L. Toop L. J Prim Health Care. 2009 Sep;1(3):234-6. J Prim Health Care. 2009. PMID: 21534329 No abstract available.
• Improving cardiovascular protection: focus on a cardiovascular polypill.

  Barrios V, Escobar C. Barrios V, et al. Future Cardiol. 2016 Mar;12(2):181-96. doi: 10.2217/fca.15.80. Epub 2015 Dec 10. Future Cardiol. 2016. PMID: 26652213 Review.
• A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.

  Carey KM, Comee MR, Donovan JL, Kanaan AO. Carey KM, et al. Ann Pharmacother. 2012 May;46(5):688-95. doi: 10.1345/aph.1Q621. Epub 2012 May 8. Ann Pharmacother. 2012. PMID: 22570437 Review.